<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137901">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01950481</url>
  </required_header>
  <id_info>
    <org_study_id>CLDK378A2110</org_study_id>
    <nct_id>NCT01950481</nct_id>
  </id_info>
  <brief_title>Effect of Hepatic Impairment on LDK378 Pharmacokinetics</brief_title>
  <official_title>A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDK378 in Subjects With Hepatic Impairment Compared to Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics and safety of 750 mg of LDK378 given once orally in subjects with impaired
      hepatic function and healthy subjects with normal hepatic function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>LDK378 pharmacokinetic parameters (Tmax, Cmax, AUClast, AUCinf, T1/2, CL/F, Vz/F)</measure>
    <time_frame>18 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the pharmacokinetics of a single dose of LDK378 in subjects with impaired hepatic function as compared to healthy subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>18 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be determined by the frequency of adverse events and the frequency of laboratory toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma protein binding of LDK378</measure>
    <time_frame>1 Day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma protein binding of LDK378</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Relationship between PK and hepatic function parameters</measure>
    <time_frame>18 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Explore the relationship between PK and hepatic function parameters</description>
  </other_outcome>
  <other_outcome>
    <measure>4β-hydroxycholesterol level</measure>
    <time_frame>18 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>4β-hydroxycholesterol level</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Normal Hepatic Function</condition>
  <condition>Impaired Hepatic Function</condition>
  <arm_group>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal hepatic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with mild hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with moderate hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe hepatic impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDK378</intervention_name>
    <description>Oral LDK378 750 mg once</description>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (all groups):

          -  Male Subjects between 18-70 years of age

          -  Female subjects between 18-70 years of age who are postmenopausal or sterile

          -  Body Mass Index (BMI) of 18.0- 35.0 kg/m2, with body weight ≥ 50 kg.

        Inclusion (group mild, moderate and severe hepatic impairment):

        - Subjects with confirmed cirrhosis

        Exclusion Criteria (all groups):

          -  impaired cardiac function

          -  concurrent severe and/or uncontrolled medical conditions

        Exclusion Criteria (moderate, mild and severe groups):

        - Clinical evidence of severe ascites
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DaVita Clinical Research-Denver</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>303-566-3008</phone>
    </contact>
    <investigator>
      <last_name>Chris Galloway</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-472-0228</phone>
    </contact>
    <investigator>
      <last_name>Thomas C. Marbury</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Miinneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-347-6206</phone>
    </contact>
    <investigator>
      <last_name>Jolene Berg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>September 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDK378</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>hepatic impairment</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
